These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34989782)

  • 1. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
    Borio LL; Bright RA; Emanuel EJ
    JAMA; 2022 Jan; 327(3):215-216. PubMed ID: 34989782
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID is here to stay: countries must decide how to adapt.
    Nature; 2022 Jan; 601(7892):165. PubMed ID: 35013606
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiviral pills could change pandemic's course.
    Couzin-Frankel J
    Science; 2021 Nov; 374(6569):799-800. PubMed ID: 34762459
    [No Abstract]   [Full Text] [Related]  

  • 4. Why scientists are racing to develop more COVID antivirals.
    Kozlov M
    Nature; 2022 Jan; 601(7894):496. PubMed ID: 35064230
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of COVID-19 in high-risk outpatients.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 Therapeutics for Nonhospitalized Patients.
    Gandhi RT; Malani PN; Del Rio C
    JAMA; 2022 Feb; 327(7):617-618. PubMed ID: 35029659
    [No Abstract]   [Full Text] [Related]  

  • 7. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 8. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hundreds of COVID trials could provide a deluge of new drugs.
    Ledford H
    Nature; 2022 Mar; 603(7899):25-27. PubMed ID: 35233098
    [No Abstract]   [Full Text] [Related]  

  • 10. Audio Interview: A New Antiviral against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Feb; 386(7):e25. PubMed ID: 35172062
    [No Abstract]   [Full Text] [Related]  

  • 11. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    Rubin R
    JAMA; 2022 Jun; 327(24):2380-2382. PubMed ID: 35675094
    [No Abstract]   [Full Text] [Related]  

  • 14. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    Rubin R
    JAMA; 2024 Oct; 332(13):1040-1042. PubMed ID: 39240544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
    N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
    Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Hagen MB; Gerhart JL
    Clin Infect Dis; 2024 Jul; 79(1):108-110. PubMed ID: 38411622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

  • 18. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
    Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
    Chagla Z
    Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    Chang LC; Chen IW; Hung KC
    J Med Virol; 2024 Feb; 96(2):e29464. PubMed ID: 38329167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.